NasdaqGS:SRPT

Stock Analysis Report

Executive Summary

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.


Similar Companies

Share Price & News

How has Sarepta Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.8%

SRPT

3.1%

US Biotechs

0.07%

US Market


1 Year Return

-36.3%

SRPT

-1.6%

US Biotechs

8.9%

US Market

Return vs Industry: SRPT underperformed the US Biotechs industry which returned -1.6% over the past year.

Return vs Market: SRPT underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

SRPTIndustryMarket
7 Day-2.8%3.1%0.07%
30 Day3.7%0.2%-0.3%
90 Day-42.7%0.9%-1.6%
1 Year-36.3%-36.3%-0.7%-1.6%11.3%8.9%
3 Year84.7%84.7%18.9%14.7%46.3%36.8%
5 Year465.8%465.8%-1.8%-6.6%62.1%44.3%

Price Volatility Vs. Market

How volatile is Sarepta Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sarepta Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SRPT ($85.55) is trading below our estimate of fair value ($366.34)

Significantly Below Fair Value: SRPT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SRPT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SRPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SRPT is overvalued based on its PB Ratio (5.8x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

71.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).

Earnings vs Market: SRPT is forecast to become profitable over the next 3 year, which is considered above average market growth.

High Growth Earnings: SRPT's loss is forecast to worsen by 0% next year.

Revenue vs Market: SRPT's revenue (54.4% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: SRPT's revenue (54.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SRPT's Return on Equity is forecast to be low in 3 years time (1%).


Next Steps

Past Performance

How has Sarepta Therapeutics performed over the past 5 years?

-20.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of -20.5% per year.

Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (83.4%).


Return on Equity

High ROE: SRPT has a negative Return on Equity (-51.89%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SRPT is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SRPT is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Sarepta Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SRPT's short term assets ($1.4B) exceeds its short term liabilities ($162.1M)

Long Term Liabilities: SRPT's short term assets (1.4B) exceeds its long term liabilities (486.5M)


Debt to Equity History and Analysis

Debt Level: SRPT's debt to equity ratio (39.2%) is considered satisfactory

Reducing Debt: SRPT's debt to equity ratio has increased from 0.6% to 39.2% over the past 5 years.


Balance Sheet

Inventory Level: SRPT has a low level of unsold assets or inventory.

Debt Coverage by Assets: SRPT's debt is covered by short term assets (assets are 3.311560x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SRPT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SRPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.2%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SRPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Sarepta Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.6yrs

Average management tenure


CEO

Doug Ingram (56yo)

2.3yrs

Tenure

US$1,433,872

Compensation

Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 28, 2017. Mr. Ingram serves as Director of Relay Therapeutics, ...


CEO Compensation Analysis

Compensation vs. Market: Doug has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the US market.

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


Management Age and Tenure

1.6yrs

Average Tenure

54yo

Average Age

Experienced Management: SRPT's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Age and Tenure

4.2yrs

Average Tenure

63.5yo

Average Age

Experienced Board: SRPT's board of directors are considered experienced (4.2 years average tenure).


Insider Trading

Insider Buying: SRPT insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$437,45516 Sep 19
Richard Barry
EntityIndividual
Role
Member of the Board of Directors
Non-Employee Director
Shares5,000
Max PriceUS$87.49
BuyUS$173,48009 Sep 19
Michael Bonney
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,000
Max PriceUS$86.74
BuyUS$219,95006 Sep 19
M. Behrens
EntityIndividual
Role
Chairman of the Board
Chairwoman
Shares2,500
Max PriceUS$87.98
BuyUS$496,59320 Aug 19
Richard Barry
EntityIndividual
Role
Member of the Board of Directors
Non-Employee Director
Shares5,000
Max PriceUS$99.32
BuyUS$453,25014 Aug 19
Richard Barry
EntityIndividual
Role
Member of the Board of Directors
Non-Employee Director
Shares3,700
Max PriceUS$122.50
BuyUS$159,25013 Aug 19
Richard Barry
EntityIndividual
Role
Member of the Board of Directors
Non-Employee Director
Shares1,300
Max PriceUS$122.50
BuyUS$2,000,16012 Aug 19
Douglas Ingram
EntityIndividual
Role
Chief Executive Officer
President
Shares16,252
Max PriceUS$123.41
BuyUS$2,009,87230 Oct 18
Douglas Ingram
EntityIndividual
Role
Chief Executive Officer
President
Shares16,695
Max PriceUS$120.94

Ownership Breakdown


Management Team

  • Doug Ingram (56yo)

    President

    • Tenure: 2.3yrs
    • Compensation: US$1.43m
  • Diane Berry

    Senior Vice President of Global Health Policy and Government & Patient Affairs

    • Tenure: 0.08yrs
  • Sandy Mahatme (54yo)

    Executive VP

    • Tenure: 6.9yrs
    • Compensation: US$4.22m
  • Ty Howton (47yo)

    Executive VP

    • Tenure: 6.9yrs
    • Compensation: US$3.13m
  • Bo Cumbo (48yo)

    Executive VP & Chief Commercial Officer

    • Tenure: 3yrs
    • Compensation: US$3.12m
  • Gary Charbonneau

    Senior VP of Global Regulatory Affairs

    • Tenure: 1.4yrs
  • Joan Nickerson

    Senior Vice President of Human Resources

    • Tenure: 0.08yrs
  • Gilmore O'Neill (54yo)

    Executive VP of R&D and Chief Medical Officer

    • Tenure: 1.3yrs
    • Compensation: US$6.67m
  • Louise Rodino-Klapac

    Senior Vice President of Gene Therapy

    • Tenure: 0.6yrs
  • Ian Estepan

    Senior VP of Corporate Affairs & Chief of Staff

    • Tenure: 1.8yrs

Board Members

  • Mike Bonney (61yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$445.25k
  • Doug Ingram (56yo)

    President

    • Tenure: 2.3yrs
    • Compensation: US$1.43m
  • M. Behrens (67yo)

    Chairwoman

    • Tenure: 4.5yrs
    • Compensation: US$502.15k
  • Hans Wigzell (81yo)

    Chairman of Corporate Strategy Board & Non-Employee Director

    • Tenure: 0yrs
    • Compensation: US$467.02k
  • Rick Barry (60yo)

    Non-Employee Director

    • Tenure: 4.3yrs
    • Compensation: US$477.35k
  • Bev Davidson

    Member of Strategic & Scientific Advisory Board

    • Tenure: 4.2yrs
  • Louis Kunkel

    Member of Strategic & Scientific Advisory Board

    • Tenure: 4.2yrs
  • Claude Nicaise (66yo)

    Non-Employee Director

    • Tenure: 4.3yrs
    • Compensation: US$464.51k
  • Kenneth Fischbeck

    Member of Strategic & Scientific Advisory Board

    • Tenure: 2.6yrs
  • Matthew Wood

    Member of Strategic & Scientific Advisory Board

    • Tenure: 2.6yrs

Company Information

Sarepta Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sarepta Therapeutics, Inc.
  • Ticker: SRPT
  • Exchange: NasdaqGS
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.360b
  • Shares outstanding: 74.34m
  • Website: https://www.sarepta.com

Number of Employees


Location

  • Sarepta Therapeutics, Inc.
  • 215 First Street
  • Suite 415
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SRPTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 1997
AB3ADB (Deutsche Boerse AG)YesCommon StockDEEURJun 1997
0L35LSE (London Stock Exchange)YesCommon StockGBUSDJun 1997

Biography

Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXO ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 23:31
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.